RT Journal Article
SR Electronic
T1 The cost of building an environmental surveillance system for typhoid
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.12.21260395
DO 10.1101/2021.07.12.21260395
A1 Brittany L. Hagedorn
A1 Nicolette A. Zhou
A1 Christine S. Fagnant-Sperati
A1 Jeffry H. Shirai
A1 Jillian Gauld
A1 Yuke Wang
A1 David S. Boyle
A1 John Scott Meschke
YR 2021
UL http://medrxiv.org/content/early/2021/07/16/2021.07.12.21260395.abstract
AB Introduction The typhoid conjugate vaccine is a safe and effective method for preventing Salmonella enterica serovar Typhi (typhoid) and the WHO’s guidance supports its use in locations with ongoing transmission. However, many countries lack a robust clinical surveillance system, making it challenging to determine where to use the vaccine. Environmental surveillance is an alternative approach to identify ongoing transmission, but the cost to implement such a strategy is previously unknown.Methods We estimated the cost of an environmental surveillance program for thirteen potential protocols. Unit costs were obtained from research labs involved in protocol development and equipment information was obtained from manufacturers and expert opinion. The cost model includes thirteen components and twenty-seven pieces of equipment. We used Monte Carlo simulations to project total costs.Results Total costs per sample including setup, overhead, and operational costs, range from $357–794 at a scale of 25 sites to $116–532 at 125 sites. Operational costs (ongoing expenditures) range from $218–584 per sample (25 sites) to $74–421 (125 sites). Eleven of the thirteen protocols have operational costs below $200 at this higher scale. Protocols with high up-front equipment costs benefit more from scale efficiencies. Sensitivity analyses show that laboratory labor, process efficiency, and the cost of consumables are the primary drivers of cost.Conclusion At scale, environmental surveillance may be affordable, depending on the protocol chosen and the geographic context. Costs will need to be considered along with protocol sensitivity. Opportunities to leverage existing infrastructure and multi-disease platforms may be necessary to further reduce costs.What is already known?Environmental surveillance has been used for polio transmission surveillance to target vaccination campaigns to prevent outbreaks. Similarly, methods for typhoid environmental surveillance are being developed, and could be used to support vaccine introduction decisions, if they are accurate and affordable.What are the new findings?Across the scenarios examined, operational costs are between $74–584 per sample depending on the scale and protocol selected. Operational costs are 67–79% of total annualized costs across the same permutations.What do the new findings imply?Policymakers can use these estimates and understanding of the efficiency of scale benefits in order to design a surveillance system that balances total cost with surveillance sensitivity and geographic coverage.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Meschke, Dr. Zhou, Ms. Fagnant-Sperati, Mr. Shirai, and Dr. Wang received grant funding from the Bill and Melinda Gates Foundation during the conduct of the study. This publication is based on models and data analysis performed by the Institute for Disease Modeling at the Bill & Melinda Gates Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available within the manuscript and supplements. Input assumptions and cost data from the survey of laboratories is summarized and available in the supplementary materials. Detailed results are also summarized in the supplementary materials and visualized within the main document. Inquiries for additional details can be made to the corresponding author ORCID iD 0000-0002-1489-7168.